|
51 |
Application of 2‐D DIGE to survey the quality of biological medicines
Enthalten in Proteomics Bd. 11, 2011, Nr. 10: 2120-2123. 4 S.
|
|
|
|
52 |
Letter: The Spence Commission and the Washington Consensus
Enthalten in The Economists' voice Bd. 5, 2008, Nr. 4. 2 S.
|
|
|
|
53 |
The Mechanism as SI GaAs Substrate Influences the Resistivity of the Epitaxial Layer
Enthalten in Crystal research and technology Bd. 27, 2006, Nr. 8: 1053-1060. 8 S.
|
|
|
|
54 |
Communicating risks of foodborne diseases
Enthalten in Open medicine Bd. 1, 2006, Nr. 1: 69-80. 12 S.
|
|
|
|
55 |
A Proportional Hazards Model of Commercial Mortgage Default with Originator Bias
Enthalten in The journal of real estate finance and economics Bd. 27, Nr. 1, date:7.2003: 5-23
|
|
|
|
56 |
A manipulative technique of Andrew Taylor Still as reported by Charles Hazzard, DO, in 1905
Enthalten in Journal of osteopathic medicine Bd. 96, 1996, Nr. 10: 597-597. 6 S.
|
|
|
|
57 |
A price and use comparison of generic versus originator cardiovascular medicines: a hospital study in Chongqing, China
Enthalten in BMC health services research Bd. 13, 5.10.2013, Nr. 1, date:12.2013: 1-8
|
|
|
|
58 |
A randomized, open-label, multi-center, active-controlled phase II study comparing abiraterone acetate tablets (II), an improved formulation, versus originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer
Enthalten in BMC medicine Bd. 23, 9.5.2025, Nr. 1, date:12.2025: 1-9
|
|
|
|
59 |
A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study
Enthalten in BMC pharmacology & toxicology Bd. 14, 5.1.2013, Nr. 1, date:12.2013: 1-19
|
|
|
|
60 |
Bioequivalence Evaluation in Healthy Volunteers: New Generic Formulations of Sitagliptin and Sitagliptin–Metformin Fixed-Dose Combination Compared with the Originator Products
Enthalten in Diabetes therapy Bd. 14, 16.12.2022, Nr. 2, date:2.2023: 347-362
|
|
Administration
